Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH
Go back to Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH| Johnson & Johnson (NYSE: JNJ) | Delayed: 228.39 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.39 | 52 Week High | $126.07 | |||
| Open | $228.39 | 52 Week Low | $94.28 | |||
| Day High | $228.39 | P/E | 47.48 | |||
| Day Low | $228.39 | EPS | $4.81 | |||
| Volume | 1,999 | |||||
